Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

计划入组 61 人 · 首次发布于 2009 年 1 月 29 日

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

计划入组 37 人 · 首次发布于 2014 年 3 月 13 日

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

计划入组 22 人 · 首次发布于 2011 年 11 月 29 日

Epcoritamab(Epkinly, Tepkinly)

Rx

Glofitamab(Columvi)

Rx

MALT-1 inhibitors (diffuse large B-cell lymphoma)

Karyopharm Therapeutics

United States

CARGO Therapeutics

United States

Nkarta

United States

Phase 1/Dose Expansion Trial of Brentuximab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Epcoritamab Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Glofitamab-gxbm (Columvi) Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma